Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
News & Analysis: Retrophin
Find out how earnings and other factors hit these stocks.
Retrophin's PKAN drug candidate missed the mark in a late-stage trial.
RTRX earnings call for the period ending June 30, 2019.
RTRX earnings call for the period ending March 31, 2019.
These two growth stocks are poised for enormous gains.
RTRX earnings call for the period ending December 31, 2018.
The biopharma's stock skyrocketed in response to strong phase 2 clinical trial results.
Shares pop on rumors of a potential buyout.
News of an incoming competitor pushed shares lower in early trading.